Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents

Jessica A. Waller, Sara Holm Nygaard, Yan Li, Kristian Gaarn Jardin, Joseph A. Tamm, Aicha Abdourahman, Betina Elfving, Alan Pehrson, Connie Sánchez, Rasmus Wernersson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The identification of biomarkers that predict susceptibility to major depressive disorder and treatment response to antidepressants is a major challenge. Vortioxetine is a novel multimodal antidepressant that possesses pro-cognitive properties and differentiates from other conventional antidepressants on various cognitive and plasticity measures. The aim of the present study was to identify biological systems rather than single biomarkers that may underlie vortioxetine's treatment effects. Results: We show that the biological systems regulated by vortioxetine are overlapping between mouse and rat in response to distinct treatment regimens and in different brain regions. Furthermore, analysis of complexes of physically-interacting proteins reveal that biomarkers involved in transcriptional regulation, neurodevelopment, neuroplasticity, and endocytosis are modulated by vortioxetine. A subsequent qPCR study examining the expression of targets in the protein-protein interactome space in response to chronic vortioxetine treatment over a range of doses provides further biological validation that vortioxetine engages neuroplasticity networks. Thus, the same biology is regulated in different species and sexes, different brain regions, and in response to distinct routes of administration and regimens. Conclusions: A recurring theme, based on the present study as well as previous findings, is that networks related to synaptic plasticity, synaptic transmission, signal transduction, and neurodevelopment are modulated in response to vortioxetine treatment. Regulation of these signaling pathways by vortioxetine may underlie vortioxetine's cognitive-enhancing properties.

Original languageEnglish
Article number56
JournalBMC Neuroscience
Volume18
Issue number1
DOIs
StatePublished - 4 Aug 2017

Fingerprint

Protein Interaction Maps
Neuronal Plasticity
Rodentia
Antidepressive Agents
Biomarkers
vortioxetine
Proteins
Major Depressive Disorder
Brain
Endocytosis
Synaptic Transmission
Signal Transduction

Keywords

  • Antidepressant
  • Multimodal
  • Network biology
  • Synaptic plasticity
  • Vortioxetine

Cite this

Waller, J. A., Nygaard, S. H., Li, Y., Jardin, K. G., Tamm, J. A., Abdourahman, A., ... Wernersson, R. (2017). Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents. BMC Neuroscience, 18(1), [56]. https://doi.org/10.1186/s12868-017-0376-x
Waller, Jessica A. ; Nygaard, Sara Holm ; Li, Yan ; Jardin, Kristian Gaarn ; Tamm, Joseph A. ; Abdourahman, Aicha ; Elfving, Betina ; Pehrson, Alan ; Sánchez, Connie ; Wernersson, Rasmus. / Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents. In: BMC Neuroscience. 2017 ; Vol. 18, No. 1.
@article{3a6e97c329d642f9a93fd70d82b0ffa9,
title = "Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents",
abstract = "Background: The identification of biomarkers that predict susceptibility to major depressive disorder and treatment response to antidepressants is a major challenge. Vortioxetine is a novel multimodal antidepressant that possesses pro-cognitive properties and differentiates from other conventional antidepressants on various cognitive and plasticity measures. The aim of the present study was to identify biological systems rather than single biomarkers that may underlie vortioxetine's treatment effects. Results: We show that the biological systems regulated by vortioxetine are overlapping between mouse and rat in response to distinct treatment regimens and in different brain regions. Furthermore, analysis of complexes of physically-interacting proteins reveal that biomarkers involved in transcriptional regulation, neurodevelopment, neuroplasticity, and endocytosis are modulated by vortioxetine. A subsequent qPCR study examining the expression of targets in the protein-protein interactome space in response to chronic vortioxetine treatment over a range of doses provides further biological validation that vortioxetine engages neuroplasticity networks. Thus, the same biology is regulated in different species and sexes, different brain regions, and in response to distinct routes of administration and regimens. Conclusions: A recurring theme, based on the present study as well as previous findings, is that networks related to synaptic plasticity, synaptic transmission, signal transduction, and neurodevelopment are modulated in response to vortioxetine treatment. Regulation of these signaling pathways by vortioxetine may underlie vortioxetine's cognitive-enhancing properties.",
keywords = "Antidepressant, Multimodal, Network biology, Synaptic plasticity, Vortioxetine",
author = "Waller, {Jessica A.} and Nygaard, {Sara Holm} and Yan Li and Jardin, {Kristian Gaarn} and Tamm, {Joseph A.} and Aicha Abdourahman and Betina Elfving and Alan Pehrson and Connie S{\'a}nchez and Rasmus Wernersson",
year = "2017",
month = "8",
day = "4",
doi = "10.1186/s12868-017-0376-x",
language = "English",
volume = "18",
journal = "BMC Neuroscience",
issn = "1471-2202",
publisher = "BioMed Central Ltd.",
number = "1",

}

Waller, JA, Nygaard, SH, Li, Y, Jardin, KG, Tamm, JA, Abdourahman, A, Elfving, B, Pehrson, A, Sánchez, C & Wernersson, R 2017, 'Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents', BMC Neuroscience, vol. 18, no. 1, 56. https://doi.org/10.1186/s12868-017-0376-x

Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents. / Waller, Jessica A.; Nygaard, Sara Holm; Li, Yan; Jardin, Kristian Gaarn; Tamm, Joseph A.; Abdourahman, Aicha; Elfving, Betina; Pehrson, Alan; Sánchez, Connie; Wernersson, Rasmus.

In: BMC Neuroscience, Vol. 18, No. 1, 56, 04.08.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents

AU - Waller, Jessica A.

AU - Nygaard, Sara Holm

AU - Li, Yan

AU - Jardin, Kristian Gaarn

AU - Tamm, Joseph A.

AU - Abdourahman, Aicha

AU - Elfving, Betina

AU - Pehrson, Alan

AU - Sánchez, Connie

AU - Wernersson, Rasmus

PY - 2017/8/4

Y1 - 2017/8/4

N2 - Background: The identification of biomarkers that predict susceptibility to major depressive disorder and treatment response to antidepressants is a major challenge. Vortioxetine is a novel multimodal antidepressant that possesses pro-cognitive properties and differentiates from other conventional antidepressants on various cognitive and plasticity measures. The aim of the present study was to identify biological systems rather than single biomarkers that may underlie vortioxetine's treatment effects. Results: We show that the biological systems regulated by vortioxetine are overlapping between mouse and rat in response to distinct treatment regimens and in different brain regions. Furthermore, analysis of complexes of physically-interacting proteins reveal that biomarkers involved in transcriptional regulation, neurodevelopment, neuroplasticity, and endocytosis are modulated by vortioxetine. A subsequent qPCR study examining the expression of targets in the protein-protein interactome space in response to chronic vortioxetine treatment over a range of doses provides further biological validation that vortioxetine engages neuroplasticity networks. Thus, the same biology is regulated in different species and sexes, different brain regions, and in response to distinct routes of administration and regimens. Conclusions: A recurring theme, based on the present study as well as previous findings, is that networks related to synaptic plasticity, synaptic transmission, signal transduction, and neurodevelopment are modulated in response to vortioxetine treatment. Regulation of these signaling pathways by vortioxetine may underlie vortioxetine's cognitive-enhancing properties.

AB - Background: The identification of biomarkers that predict susceptibility to major depressive disorder and treatment response to antidepressants is a major challenge. Vortioxetine is a novel multimodal antidepressant that possesses pro-cognitive properties and differentiates from other conventional antidepressants on various cognitive and plasticity measures. The aim of the present study was to identify biological systems rather than single biomarkers that may underlie vortioxetine's treatment effects. Results: We show that the biological systems regulated by vortioxetine are overlapping between mouse and rat in response to distinct treatment regimens and in different brain regions. Furthermore, analysis of complexes of physically-interacting proteins reveal that biomarkers involved in transcriptional regulation, neurodevelopment, neuroplasticity, and endocytosis are modulated by vortioxetine. A subsequent qPCR study examining the expression of targets in the protein-protein interactome space in response to chronic vortioxetine treatment over a range of doses provides further biological validation that vortioxetine engages neuroplasticity networks. Thus, the same biology is regulated in different species and sexes, different brain regions, and in response to distinct routes of administration and regimens. Conclusions: A recurring theme, based on the present study as well as previous findings, is that networks related to synaptic plasticity, synaptic transmission, signal transduction, and neurodevelopment are modulated in response to vortioxetine treatment. Regulation of these signaling pathways by vortioxetine may underlie vortioxetine's cognitive-enhancing properties.

KW - Antidepressant

KW - Multimodal

KW - Network biology

KW - Synaptic plasticity

KW - Vortioxetine

UR - http://www.scopus.com/inward/record.url?scp=85026796486&partnerID=8YFLogxK

U2 - 10.1186/s12868-017-0376-x

DO - 10.1186/s12868-017-0376-x

M3 - Article

C2 - 28778148

AN - SCOPUS:85026796486

VL - 18

JO - BMC Neuroscience

JF - BMC Neuroscience

SN - 1471-2202

IS - 1

M1 - 56

ER -